What it does
Incanthera plc (AQSE:INC) is a revenue-generating, UK-based, oncology therapeutics company focusing on drug discovery and development of targeted medicines for the treatment of cancer.
It is developing a pipeline of tumour-targeting drug delivery systems. The platform technology enables precise delivery of both new and existing highly potent drugs directly to tumours. This precision improves tumour selectivity and decreasing the side effects associated with traditional anti-cancer treatments.
It was spun-out in 2010 from the Institute of Cancer Therapeutics at the University of Bradford.
Its Sol cream has already gone through the proof of concept stage and Incanthera is looking for a partner within 12-18 months to help it through the product development and marketing stage.
Sol is a proprietary topical formulation designed to deliver an active agent into the skin that is known to prevent the formation of solar (actinic) keratosis and skin cancer: the technology uses a proprietary formulation and prodrug targeting technologies to deliver treatment specifically to the tumour.
How it is doing
February marked the firm's first year since debuting the Aquis Growth Market: in fact, the therapeutics company floated on February 28, 2020, raising funds to concentrate on the commercialisation of Sol.
Meanwhile, the specialist oncology company has prioritised discussions with two global cosmetic companies to licence lead asset Sol's technology to commercial partners.
It is also separately exploring working with potential partners to apply its expertise and technology to develop further targeted products, including a partnership that could provide new sun factor protection technology being used in conjunction with Sol.
Incanthera expects to provide an update on discussions around the time of its annual results announcement in June.
What the boss says: Tim McCarthy, chairman
“We have seen significant value addition during these six months, with the solid progression of our lead asset Sol, together with strong financial control, and investment from subscription agreements entered into at the time of the company's IPO."
Video
